Jack Anders Sells 3,104 Shares of Revolution Medicines (NASDAQ:RVMD) Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) CFO Jack Anders sold 3,104 shares of Revolution Medicines stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $77.09, for a total value of $239,287.36. Following the sale, the chief financial officer directly owned 108,065 shares of the company’s stock, valued at $8,330,730.85. This represents a 2.79% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Revolution Medicines Price Performance

NASDAQ:RVMD opened at $78.78 on Friday. Revolution Medicines, Inc. has a 52 week low of $29.17 and a 52 week high of $81.49. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.05 and a current ratio of 8.05. The firm’s 50-day simple moving average is $66.73 and its 200 day simple moving average is $49.21. The firm has a market cap of $15.23 billion, a price-to-earnings ratio of -15.24 and a beta of 0.96.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($1.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.22). During the same quarter in the prior year, the business posted ($0.94) EPS. As a group, sell-side analysts predict that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

More Revolution Medicines News

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: First patient randomized in RASolute‑304 (daraxonrasib) resectable pancreatic cancer trial — a near‑term clinical milestone that validates program progress and can support longer‑term revenue potential if subsequent data are positive. Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial
• Neutral Sentiment: Analyst coverage remains largely positive (consensus Buy/Strong Buy with an average target near $78.50), which provides support for the stock but already factors in pipeline strengths.
• Neutral Sentiment: Institutional ownership is very high (reported ~94%); recent reported changes were small. High institutional concentration can amplify moves on news but also limits free float liquidity. RVMD Institutional Ownership and Stock Profile
• Negative Sentiment: Several insiders sold meaningful share blocks (CFO Jack Anders, COO Margaret Horn and other executives sold on Dec. 16), which can be interpreted as profit‑taking or a signal for caution; aggregated insider selling may weigh on sentiment near term. Insider Selling: Revolution Medicines (NASDAQ:RVMD) CFO Sells 3,104 Shares of Stock

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Wells Fargo & Company boosted their price objective on Revolution Medicines from $67.00 to $70.00 and gave the company an “overweight” rating in a report on Thursday, September 11th. Raymond James Financial increased their price target on Revolution Medicines from $72.00 to $76.00 and gave the company a “strong-buy” rating in a research report on Friday, October 17th. Mizuho started coverage on shares of Revolution Medicines in a research note on Tuesday, October 21st. They issued an “outperform” rating and a $90.00 target price on the stock. UBS Group raised shares of Revolution Medicines to a “strong-buy” rating in a report on Thursday, December 4th. Finally, Truist Financial began coverage on Revolution Medicines in a report on Friday, September 5th. They set a “buy” rating and a $99.00 price objective for the company. Four analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $78.50.

Institutional Investors Weigh In On Revolution Medicines

A number of institutional investors and hedge funds have recently modified their holdings of the company. CWM LLC raised its position in shares of Revolution Medicines by 171.3% in the second quarter. CWM LLC now owns 917 shares of the company’s stock worth $34,000 after buying an additional 579 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Revolution Medicines by 45.1% in the 3rd quarter. GAMMA Investing LLC now owns 837 shares of the company’s stock valued at $39,000 after acquiring an additional 260 shares in the last quarter. Banque Transatlantique SA bought a new stake in shares of Revolution Medicines during the 1st quarter valued at about $42,000. Quarry LP purchased a new position in Revolution Medicines in the 1st quarter worth approximately $50,000. Finally, Twin Tree Management LP bought a new position in shares of Revolution Medicines in the 1st quarter worth $58,000. 94.34% of the stock is owned by hedge funds and other institutional investors.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.